Thalidomide as an Immunotherapeutic Agent: The Effects on Neutrophil- Mediated Inflammation

E-ISSN： 1873-4286|11|3|395-401

ISSN： 1381-6128

Source： Current Pharmaceutical Design, Vol.11, Iss.3, 2005-02, pp. : 395-401

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Neutrophil-Derived Cytokines: Potential Therapeutic Targets in Inflammation

Current Drug Targets. Inflammation & Allergy, Vol. 4, Iss. 3, 2005-06 ,pp. : 273-279

Bentham Science Publishers

Access to resources Recommend Favorite

New Potential Targets to Modulate Neutrophil Function in Inflammation

Mini Reviews in Medicinal Chemistry, Vol. 9, Iss. 2, 2009-02 ,pp. : 153-168

Bentham Science Publishers

Access to resources Recommend Favorite

The Molecular Mechanisms of Glucocorticoids-Mediated Neutrophil Survival

Current Drug Targets, Vol. 12, Iss. 4, 2011-04 ,pp. : 556-562

Bentham Science Publishers

Access to resources Recommend Favorite

Mechanisms of Neutrophil-mediated Disease: Innovative Therapeutic Interventions

Current Pharmaceutical Design, Vol. 18, Iss. 12, 2012-04 ,pp. : 1609-1619

Bentham Science Publishers

Access to resources Recommend Favorite

Prevention of Recurrent Respiratory Tract Infections in Children Using a Ribosomal Immunotherapeutic Agent: A Clinical Review

By Bousquet Jean

Pediatric Drugs, Vol. 8, Iss. 4, 2006-01 ,pp. : 235-243

Adis International

Access to resources Recommend Favorite